STOCKHOLM, April 23,
2024 /PRNewswire/ -- Today, 23 April 2024, the subscription period
in SciBase Holding AB (publ) ('SciBase' or the 'Company')
rights issue of units of up to approximately SEK 15 million commences (the 'Rights Issue').
The Rights Issue was resolved by the Board of Directors in SciBase
on 5 April 2024, pursuant to the
authorisation granted by the Annual General Meeting held on
17 May 2023.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR
DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG
KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH
AFRICA, THE UNITED STATES
OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART,
WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER
TO BUY SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO THE
SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT.
Summary of the Rights Issue
- Upon full subscription in the Rights Issue, SciBase will
receive issue proceeds of approximately SEK
15 million before deduction of transaction costs.
- For each share held in the Company on the record date,
19 April 2024, the holder received
one (1) unit right. Ten (10) unit rights entitle the holder to
subscribe for three (3) units. One (1) unit consists of one (1) new
share and five (5) warrants of series TO 2.
- The subscription price is set to SEK
0.42 per unit, corresponding to SEK
0.42 per share. The warrants of series TO 2 are issued free
of charge.
- If the Rights Issue is fully subscribed and upon full exercise
of warrants of series TO 2, the Company is expected to raise up to
an additional amount of approximately SEK 75
million, before deduction of transaction costs.
- The shareholder Morningside Group AB and Members of the Board
of Directors and management have undertaken to subscribe for units
representing approximately 16.6 percent of the Rights Issue. The
subscription commitments are not secured through bank guarantees,
restricted funds, pledged assets or similar arrangements.
- The record date for the Rights Issue was 19 April 2024 and the subscription period in the
Rights Issue is from and including 23 April
2024 until and including 7 May
2024.
- Warrants of series TO 2 can be exercised for subscription of
shares to a subscription price of SEK
0.42 per share from and including 3
April 2029 until and including 17
April 2029.
Prospectus
Complete information regarding the Rights Issue and information
about the Company can be found in the prospectus published on
19 April 2024. The prospectus is
available on the Company's website
(http://investors.scibase.se/en), on Vator Securities' website
(www.vatorsecurities.se) and on the Swedish Financial
Supervisory Authority's website (www.fi.se).
Timetable for the Rights Issue
23 April 2024 – 2 May
2024
|
Trading in unit
rights
|
23 April 2024 – 7 May
2024
|
Subscription
period
|
23 April 2024 – 27 May
2024
|
Trading in
BTU
|
Around 10 May
2024
|
Announcement of the
outcome of the Rights Issue
|
3 April 2029 – 17 April
2029
|
Subscription period for
warrants of series TO 2
|
Advisors
Vator Securities is the financial advisor and Advokatfirman
Schjødt is the legal advisor to SciBase in connection with the
Rights Issue.
For additional information, please contact:
Pia Renaudin, VD,
tel. +46732069802,
e-mail: pia.renaudin@scibase.com
Certified Advisor (CA)
Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se
About SciBase
SciBase is a global medical technology company, specializing in
early detection and prevention in dermatology. SciBase develops and
commercializes Nevisense, a unique point-of-care platform that
combines AI (artificial intelligence) and advanced EIS technology
to elevate diagnostic accuracy, ensuring proactive skin health
management.
Our commitment is to minimize patient suffering, allowing
clinicians to improve and save lives through timely detection and
intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in
dermatological advancements.
The Company has been on the Nasdaq First North Growth Market
exchange since June 2, 2015. Learn
more at www.scibase.com. All press releases and financial reports
can be found
here: http://investors.scibase.se/en/pressreleases
Important information
Publication, release or distribution of this press release may
in certain jurisdictions be subject to legal restrictions and
persons in the jurisdictions where this press release has been made
public or distributed should be informed of and follow such legal
restrictions. The recipient of this press release is responsible
for using this press release and the information herein in
accordance with applicable rules in each jurisdiction. This press
release does not constitute an offer or solicitation to buy or
subscribe for any securities in SciBase in any jurisdiction, either
from SciBase or from anyone else.
This press release is not a prospectus according to the
definition in Regulation (EU) 2017/1129 (the "Prospectus
Regulation") and has not been approved by any regulatory
authority in any jurisdiction. Any acquisition of units in SciBase
in the Rights Issue should only be made on the basis of the
information contained in the formal prospectus issued in connection
with the Rights Issue, which was approved by the Swedish Financial
Supervisory Authority on 19 April
2024. In accordance with article 2
k of the Prospectus Regulation this press release
constitutes an advertisement.
This press release does not constitute an offer or solicitation
to buy or subscribe for securities in the
United States. The securities mentioned herein may not be
sold in the United States without
registration, or without an exemption from registration, under the
U.S. Securities Act from 1933 ("Securities Act") and may not
be offered or sold within the United
States without being registered, covered by an exemption
from, or part of a transaction that is not subject to the
registration requirements according to the Securities Act. There is
no intention to register any securities mentioned herein in
the United States or to issue a
public offering of such securities in the
United States. The information in this press release may not
be released, published, copied, reproduced or distributed, directly
or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong
Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South
Africa, the United States
or any other jurisdiction where the release, publication or
distribution of this information would violate current rules or
where such an action is subject to legal restrictions or would
require additional registration or other measures beyond those that
follow from Swedish law. Actions in contravention of this
instruction may constitute a violation of applicable securities
legislation.
Forward-looking statements
This press release contains forward-looking statements related
to the Company's intentions, estimates or expectations with regard
to the Company's future results, financial position, liquidity,
development, outlook, estimated growth, strategies and
opportunities as well as the markets in which the Company is
active. Forward-looking statements are statements that do not refer
to historical facts and can be identified by the use of terms such
as "believes," "expects," "anticipates," "intends," "estimates,"
"will," "may," "implies," "should," "could" and, in each case,
their negative, or comparable terminology. The forward-looking
statements in this press release are based on various assumptions,
which in several cases are based on further assumptions. Although
the Company believes that the assumptions reflected in these
forward-looking statements are reasonable, there is no guarantee
that they will occur or that they are correct. Since these
assumptions are based on assumptions or estimates and involve risks
and uncertainties, actual results or outcomes, for many different
reasons, may differ materially from those what is stated in the
forward-looking statements. Due to such risks, uncertainties,
eventualities and other significant factors, actual events may
differ materially from the expectations that expressly or
implicitly are contained in this press release through the
forward-looking statements. The Company does not guarantee that the
assumptions which serve as a basis for the forward-looking
statements in this press release are correct, and each reader of
the press release should not rely on the forward-looking statements
in this press release. The information, opinions and
forward-looking statements that expressly or implicitly are stated
herein are provided only as of the date of this press release and
may change. Neither the Company nor any other party will review,
update, confirm or publicly announce any revision of any
forward-looking statement to reflect events that occur or
circumstances that arise with respect to the contents of this press
release, beyond what is required by law or Nasdaq First North
Growth Market Rulebook for Issuers of Shares.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/scibase/r/today-is-the-first-day-of-the-subscription-period-in-scibase-rights-issue,c3965143
The following files are available for download:
https://mb.cision.com/Main/12371/3965143/2748496.pdf
|
SciBase - Subscription
period commences
|
View original
content:https://www.prnewswire.co.uk/news-releases/today-is-the-first-day-of-the-subscription-period-in-scibase-rights-issue-302124171.html